RxDoctor Payments Data

Andrea Fox, PA

Physician Assistant · Stanford, CANPI 1508217613

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $114,234 of the $172,121 with a category attached, or 66.4%. Amgen accounts for 87.1% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $118,322, more than ten times the $353 reported in 2021. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$172,121in general payments, 2019–2025

Across 363 payments — averaging $474.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$150K
  • Radius Health, Inc.$21K
  • UCB, Inc.$682
  • Kyowa Kirin, Inc.$139
  • Medical Device Business Services, Inc.$98
  • Ascendis Pharma Endocrinology Inc$45

What the payments were for

  • Consulting fees$11,2477%
  • Speaking & faculty fees$114,23466%
  • Travel & lodging$36,36521%
  • Food & beverage$10,1656%
  • Education$1100%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$172,121 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$91,276
Medicare patients
544
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide377$995,648
Teriparatide149$350,337
ForteoTeriparatide54$223,146
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic220$6,559
Raloxifene Hcl17$1,033
Ultra-Fine Short Pen NeedlePen Needle, Diabetic20$559
Vitamin D2Ergocalciferol (Vitamin D2)16$289
Alendronate Sodium31$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$21,184$995,648377 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →